The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $19.78 for the day, down -2.13% from the previous closing price of $20.21. In other words, the price has decreased by -$0.43 from its previous closing price. On the day, 1409597 shares were traded. DNLI stock price reached its highest trading level at $20.89 during the session, while it also had its lowest trading level at $19.68.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.65 and its Current Ratio is at 13.65. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 15 when SATO VICKI L sold 1,666 shares for $18.37 per share. The transaction valued at 30,604 led to the insider holds 121,375 shares of the business.
Schuth Alexander O. sold 20,128 shares of DNLI for $355,460 on Feb 14. The COFO and Secretary now owns 187,341 shares after completing the transaction at $17.66 per share. On Feb 14, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 1,405 shares for $17.79 each. As a result, the insider received 24,995 and left with 143,605 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2.79B and an Enterprise Value of 1.80B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.27 while its Price-to-Book (P/B) ratio in mrq is 2.66. Its current Enterprise Value per Revenue stands at 5.46 whereas that against EBITDA is -10.02.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $15.45. The 50-Day Moving Average of the stock is 18.72, while the 200-Day Moving Average is calculated to be 23.01.
Shares Statistics:
DNLI traded an average of 1.19M shares per day over the past three months and 1.93M shares per day over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 111.20M. Insiders hold about 19.54% of the company’s shares, while institutions hold 78.89% stake in the company. Shares short for DNLI as of Feb 15, 2024 were 10.82M with a Short Ratio of 9.09, compared to 9.88M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.83% and a Short% of Float of 9.29%.
Earnings Estimates
The firm’s stock currently is rated by 11 analysts. On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.6 and a low estimate of -$0.89, while EPS last year was -$0.8. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.51 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.1 and -$3.5 for the fiscal current year, implying an average EPS of -$2.87. EPS for the following year is -$2.24, with 12 analysts recommending between $2.06 and -$3.8.
